

16th Annual Pacific Psychopharmacology Conference



2022 FACULTY DISCLOSURE STATEMENTS

In accordance with Accreditation Council of Continuing Medical Education (ACCME) Standards for Commercial Support, all faculty participation in these programs are expected to disclose to the program audiences any real or apparent conflict of interest related to the content of their preparation.

| FIRST NAME | LAST NAME | DISCLOSURES | OFF-LABEL RECOMMENDATIONS? |
|------------|-----------|---|----------------------------|
| Ataa | Azarbar | Did Not Receive Disclosure | — |
| Chad | Bousman | <p>Received Payments:</p> <ul style="list-style-type: none"> • Sequence2Script Inc <ul style="list-style-type: none"> ○ I am the founder and CEO. Sequence2Script is a free tool to assist with the translation of pharmacogenetic information into evidence-based prescribing recommendations. <p>Received Funding:</p> <ul style="list-style-type: none"> • Alberta Children's Hospital Foundation, Alberta Innovates, Innovate Calgary <ul style="list-style-type: none"> ○ I was a grantee. The research funded is associated, in part, with the content of my presentations. | No |
| Shauna | Correia | <p>Received Payments:</p> <ul style="list-style-type: none"> • Vancouver Island IBD Forum <ul style="list-style-type: none"> ○ I spoke at an IBD conference, which is completely unrelated to the topic being discussed at this conference Ferring Pharmaceuticals | Yes |
| Miriam | Driscoll | Nothing to Disclose | Yes |
| Annemarie | Falk | Nothing to Disclose | N/A |
| Katelyn | Halpape | <p>Received Payments:</p> <ul style="list-style-type: none"> • Clinical Handbook of Psychotropic Drugs <ul style="list-style-type: none"> ○ Honoraria as a chapter editor <p>Received Funding:</p> <ul style="list-style-type: none"> • Health Canada Substance Use and Addiction Program and Indigenous Services Canada <ul style="list-style-type: none"> ○ Funding received to development, implement, and evaluate the USask Chronic Pain Clinic | N/A |
| Oliver | Howes | <p>Disclosures:</p> <ul style="list-style-type: none"> • Dr Howes is a part-time employee of H. Lundbeck A/S and has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand, Recordati, Roche and Viatrix/ Mylan. Neither Dr Howes or his family have holdings/ a financial stake in any pharmaceutical company. Dr Howes has a patent for the use of dopaminergic imaging. These relationships have no direct influence on the presentation he is delivering. | Yes |
| Sidney | Kennedy | <p>Received Payments:</p> <ul style="list-style-type: none"> • Abbvie, Boehringer-Ingelheim, Janssen, Lundbeck, Lundbeck Institute, Merck, Otsuka, Pfizer, Sunovion and Servier. <ul style="list-style-type: none"> ○ These relationships have not influenced my presentation. <p>Received Research Support Funding:</p> <ul style="list-style-type: none"> • Abbott, Brain Canada, CIHR (Canadian Institutes of Health Research), Janssen, Lundbeck, Ontario Brain Institute, Otsuka, Pfizer, SPOR (Canada's Strategy for Patient-Oriented Research) | No |

| | | | |
|-----------|------------|---|------------|
| | | <ul style="list-style-type: none"> ○ These relationships have not influenced my presentation. Investments: <ul style="list-style-type: none"> ● I have stock/stock options in Field Trip Health <ul style="list-style-type: none"> ○ This relationship has not influenced my presentation | |
| Nickie | Mathew | Did Not Receive Disclosure | — |
| Harish | Neelakant | Received Payments: <ul style="list-style-type: none"> ● Otsuka and Lundbeck <ul style="list-style-type: none"> ○ I was a consultant for them at a meeting related to antipsychotic depot injection dosage and initiation. I will not be talking about any specific antipsychotic depot medication or mention them by name. | No |
| Tejal | Patel | Membership: <ul style="list-style-type: none"> ● Relay Medical, Healthcare Excellence Canada <ul style="list-style-type: none"> ○ My relationship with Healthcare Excellence Canada does not focus on the use of medication adherence technology. My relationship with Relay Medical focuses on providing advise to the organization on the development of their dispensing technology. This technology is a prototype. I will mention it in the presentation alongside other technology that is also being developed. Received Funding: <ul style="list-style-type: none"> ● Pack4U, Jones Healthcare Group <ul style="list-style-type: none"> ○ I have been involved in conducting research with products from both companies. Both have supported research related to their products. I will be presenting the results of our research within the presentation. The research has been published after a peer-review process. | No |
| Bernie | Pauly | Nothing to Disclose | Yes |
| Tamara | Pringsheim | Received Funding: <ul style="list-style-type: none"> ● Alberta Health, Alberta Children's Hospital Research Institute, Public Health Agency of Canada <ul style="list-style-type: none"> ○ This funding has been for research and is paid to my institution. The funding does not influence the program content I am developing. | Yes |
| Francois | Proulx | Received Payments <ul style="list-style-type: none"> ● Fraser Health Authority, Provincial Health Services Authority <ul style="list-style-type: none"> ○ Contracted physician for provision of clinical services and medical administration. No influence on content. | Yes |
| Reza | Rafizadeh | Nothing to Disclose | N/A |
| Christian | Schütz | Received Payments: <ul style="list-style-type: none"> ● Clearmind <ul style="list-style-type: none"> ○ Consulting for medication development (alcohol use disorder) preclinical Received Funding: <ul style="list-style-type: none"> ● CIHR, Health Canada, CCSA, Brain and Behavior, UBC, PHSA | Yes |
| Jacky | Siu | Received Payments: <ul style="list-style-type: none"> ● Hogrefe Publishing <ul style="list-style-type: none"> ○ Chapter editor for Clinical Handbook of Psychotropic Drugs in 2020 | N/A |
| Julian | Somers | Received Funding: <ul style="list-style-type: none"> ● Michael Smith Foundation for Health Research, BC Construction Safety Alliance, Canadian Institutes for Health Research, BC Ministry of Health, AB Ministry of Health <ul style="list-style-type: none"> ○ Funders have not influenced the program or content that I am developing and will deliver | No |
| Jane | Sun | Nothing to Disclose | No |

| | | | |
|---------|-----------|---|-----|
| Karen | Urbanoski | Nothing to Disclose | Yes |
| Randall | White | <p>Received Payments:</p> <ul style="list-style-type: none"> • HLS Therapeutics (for profit enterprise), Canadian Agency for Drugs and Technologies in Health (non-profit regulatory agency) <ul style="list-style-type: none"> ○ I have received payments for attending discussions, reviewing documents and submitting comments related to medications and health care technology. This involved three medications and two technologies available in Canada. The invited conference speakers and their presentations are not focusing on these products to my knowledge. I have discussed an HLS product with one presenter, Dr. Harish Neelakant, who has also attended an event sponsored by the company. This to my knowledge is not a focus of his presentation and I am at arms length from this content. <p>Memberships:</p> <ul style="list-style-type: none"> • HLS Therapeutics <ul style="list-style-type: none"> ○ I have received payments for attending discussions with company marketing representatives related to medications and health care technology. The invited conference speakers and their presentations are not related to the company's products to my knowledge. | N/A |